Seattle genomics startup Variant Bio signs deal with Novo Nordisk worth up to $50M

Seattle-based Variant Bio announced a multi-year partnership with Novo Nordisk for using genomic information in treating metabolic diseases such as obesity and diabetes, totaling up to $50 million for the biotech startup.

David Moller, Variant’s chief scientist, states, “We hope that a deeper understanding of the relationships between genetic variation and metabolic traits will yield novel targets and ultimately lead to better and more diverse treatment options for people around the globe.”

By partnering with an experienced metabolic disease drug discovery team, Variant is poised to translate their genetic findings into treatments that will improve patient outcomes.

READ THE STORY at GeekWire »